Radiopharm Theranostics
Sydney, New South Wales, Australia · Biotechnology, Health Care, Medical
Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.
Key facts
- Headquarters
- Sydney, New South Wales, Australia
- Employees
- 14
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (RADX)
- Website
- radiopharmtheranostics.com
- Company page
Recent activity at Radiopharm Theranostics
- : Radiopharm Theranostics Appoints Aaron Laurita as Chief Financial Officer
- : Radiopharm Theranostics has raised A$35 million through a private placement led by Lantheus Holdings, Inc. The funds will be used for the development of radiopharmaceutical products.
- : Radiopharm Theranostics partners with BAMF Health for brain cancer study
Radiopharm Theranostics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Post-IPO Equity | $35.0M |
Leadership
- Aaron Laurita, Chief Financial Officer
- Riccardo Canevari, Chief Executive Officer
- Dimitris Voliotis, Chief Medical Officer
Verified email and direct lines for Radiopharm Theranostics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Radiopharm Theranostics in the news
- Radiopharm Theranostics Announces Positive Data from the - GlobeNewswire (Sep 09, 2026)
- Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference - Investing News Network (May 07, 2025)
- Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update - Investing News Network (Jul 29, 2025)
- Radiopharm Theranostics Reports Business Update - GlobeNewswire (Jul 31, 2026)
- Radiopharm Theranostics Signs Agreement With NorthStar Medical Radioisotopes for the Supply of Non-Carrier Added (n.c.a.) Actinium-225 - Business Wire (Oct 26, 2022)
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial - GlobeNewswire (Aug 20, 2026)
- Radiopharm Theranostics Doses First Patient in Second - GlobeNewswire (Aug 26, 2026)
- Radiopharm Theranostics Completes Enrollment in U.S. Phase - GlobeNewswire (Apr 16, 2026)
Companies similar to Radiopharm Theranostics
- Moberg Analytics · Biotechnology, Health Care, Medical
- 52North · Biotechnology, Health Care, Medical
- Carecubes · Biotechnology, Health Care, Medical
- Swarm Oncology Ltd · Biotechnology, Health Care, Medical
- AudioCure Pharma · Biotechnology, Health Care, Medical
About Radiopharm Theranostics: questions and answers
What does Radiopharm Theranostics do?
Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.
Where is Radiopharm Theranostics headquartered?
Radiopharm Theranostics is headquartered in Sydney, New South Wales, Australia.
How many employees does Radiopharm Theranostics have?
Radiopharm Theranostics has about 14 employees.
Has Radiopharm Theranostics raised funding?
Yes. Fundz has recorded 1 funding event for Radiopharm Theranostics. The most recent, Post-IPO Equity of $35.0M, was in Oct 2025.
Who leads Radiopharm Theranostics?
Riccardo Canevari is a Chief Executive Officer at Radiopharm Theranostics.
What is the latest news on Radiopharm Theranostics?
On Jun 01, 2026, Radiopharm Theranostics Appoints Aaron Laurita as Chief Financial Officer
Is Radiopharm Theranostics a public company?
Yes. Radiopharm Theranostics is publicly traded under the ticker RADX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy